RedHill Biopharma Ltd.
RDHL
$2.26
$0.199.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 80.88% | 80.88% | -302.89% | -263.18% | 62.07% |
| Total Depreciation and Amortization | -50.37% | -50.37% | 100.35% | -89.92% | -90.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -89.71% | -89.71% | -104.61% | 260.78% | -70.82% |
| Change in Net Operating Assets | 102.19% | 102.19% | 108.52% | -185.56% | -1,161.70% |
| Cash from Operations | 82.36% | 82.36% | 70.80% | -272.68% | -49.68% |
| Capital Expenditure | -100.00% | -100.00% | 92.86% | -- | 90.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -172.73% | -172.73% | 92.86% | -- | 125.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 62.12% | 62.12% | 29.35% | 23.70% | 52.82% |
| Issuance of Common Stock | -100.00% | -100.00% | -- | -41.58% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -91.15% | -91.15% | -98.66% | -- | 181.86% |
| Cash from Financing | -96.89% | -96.89% | 131,566.67% | 15.44% | 245.31% |
| Foreign Exchange rate Adjustments | 178.95% | 178.95% | -116.67% | 40.63% | 26.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -86.41% | -86.41% | 108.08% | -114.98% | 93.95% |